AbCellera Biologics Inc. ABCL
Set alert
At close · Oct 30
After hours · Oct 30, 6:39 PM ET
- YTD
- +258.77%
- 1 year
- +128.92%
- Open
- 12.60
- Prev close
- 13.08
- Mkt cap
- 3.98B
- Vol
- 3.88M
- Avg vol
- 6.42M
- EPS
- -0.54
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.75
- High
- 12.91
- Forward P/E
- -15.97
- Beta
- 1.41
- Short ratio
- 5.65
- Inst. own
- 36.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 12.27
- 200-d avg
- 6.81
- 1y target
- 16.82
5D chart
Signals (110)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:45 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:40 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
-
2 weeks ago benzinga.com
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18
UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.
3 weeks ago businesswire.com
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
1 month ago businesswire.com
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
1 month ago defenseworld.net
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings…
-
1 month ago benzinga.com
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17
JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.
-
1 month ago benzinga.com
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
1 month ago zacks.com
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
-
1 month ago benzinga.com
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30…
1 month ago businesswire.com
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
1 month ago businesswire.com
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
2 months ago defenseworld.net
BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and…
2 months ago benzinga.com
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
2 months ago benzinga.com
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
2 months ago benzinga.com
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
2 months ago seekingalpha.com
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO…
2 months ago businesswire.com
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
2 months ago benzinga.com
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at…
2 months ago benzinga.com
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.
2 months ago benzinga.com
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
-
2 months ago benzinga.com
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to…
2 months ago businesswire.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
2 months ago defenseworld.net
Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an…
2 months ago seekingalpha.com
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
2 months ago benzinga.com
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
2 months ago benzinga.com
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
2 months ago gurufocus.com
AbCellera Stock Jumps 33% on a Positive Menopause Trial
AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experimental menopause drug ABCL635 met both primary goals in a Ph
2 months ago benzinga.com
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.
2 months ago marketbeat.com
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report…
2 months ago gurufocus.com
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an
-
2 months ago benzinga.com
AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
-
2 months ago benzinga.com
Market-Moving News for August 10th
BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portuguese National Security Agency ABCL: 24% | AbCellera Reports Phase 2 Trial Results Showing…
2 months ago reuters.com
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.
-
2 months ago benzinga.com
AbCellera Reports Phase 2 Trial Results Showing Significant Symptom Reduction, Improved Sleep, And Favorable Tolerability For ABCL635
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
2 months ago businesswire.com
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
-
2 months ago benzinga.com
AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10
Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of…
-
2 months ago benzinga.com
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12
Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.
-
2 months ago benzinga.com
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of…
-
3 months ago benzinga.com
Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
4 months ago benzinga.com
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.
-
4 months ago benzinga.com
Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific Antibodies
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to developJazz…
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
5 months ago benzinga.com
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year.…
-
6 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.
-
6 months ago benzinga.com
AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11
AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic…